Acquisitions12 Dec 2025, 02:35 pm
Eiko Lifesciences to Acquire 51% Stake in SSM Formulations, Enhancing Global Footprint in Finished Dosage Forms
AI Summary
Eiko Lifesciences Limited, a leading supplier of specialty chemicals and Active Pharmaceutical Ingredients (APIs), has announced a definitive agreement to acquire a 51% equity stake in SSM Formulations Private Limited. This acquisition marks a transformative milestone for Eiko, evolving it from a Speciality chemicals and API supplier into a fully integrated pharmaceutical player with a global footprint in Finished Dosage Forms (FDF). The transaction will be executed in a phased manner aligned with Eiko's strategic fundraising through Warrants.
Key Highlights
- Eiko to acquire 51% stake in SSM Formulations, a Hinganghat Wardha based pharmaceutical formulations company.
- SSM operates a WHO-GMP accredited facility with a capacity to reach an annual capacity of 300 crore tablets and 90 crore capsules.
- SSM has high-barrier capabilities with narcotics license, registrations in several countries, and WHO-GMP certification.
- SSM's therapeutic strength lies in a portfolio across anti-diabetic, cardiac, antibiotic, pain management, dermatology, and anti-protozoal therapies.
- Eiko aims to transform SSM into a global export hub, targeting a rapid scale-up to 90% capacity utilization.